Acorda Therapeutics, Inc. (NASDAQ:ACOR)
A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.
- Quote
- Commentary
- Scorecard
- Historical Prices
- Chart
- Stats
- Ratios
- Earnings/Growth Rates
- Statements
- SEC Filings
Recs
portefeuille
(99.81)
Submitted: 12/15/2011 9:17:24 PM :
Start Price:
$21.19
ACOR Score:
+2.58
There are currently 70 ACOR shares in my "fund" with break-even of around 8.18 USD.
http://caps.fool.com/Blogs/fund-trades/678775.
Recs
Haugurafpeningum
(98.39)
Submitted: 11/8/2011 2:28:44 AM :
Start Price:
$23.23
ACOR Score:
+3.65
Technical Monthly
Recs
Recs
zzlangerhans
(99.26)
Submitted: 10/13/2010 10:45:03 PM :
Start Price:
$28.13
ACOR Score:
-23.16
Acorda seems to be wandering in a sine wave pattern as alternatively optimistic and pessimistic views of the commercial potential of their multiple sclerosis drug Ampyra. Ampyra is far from a proven winner but the share price will likely rebound with the next quarterly PR. In the meantime, Acorda has lowered their burn substantially and maintains a decent cash position.
Recs
tttchicattt
(75.44)
Submitted: 10/8/2010 2:25:40 AM :
Start Price:
$29.87
ACOR Score:
+30.61
tspy rec
Recs
Recs
doohoo
(< 20)
Submitted: 7/1/2010 4:05:46 PM :
Start Price:
$29.88
ACOR Score:
-45.17
Recent launch of new drug already improved earnings vs 2009, several potential high earning drugs in pipeline.
Recs
jimswarthout
(< 20)
Submitted: 6/1/2010 1:05:21 PM :
Start Price:
$35.20
ACOR Score:
-50.82
Ampyra is ridiculously effective if you have MS
Recs
Antipopnfresh100
(55.88)
Submitted: 4/8/2010 8:56:07 PM :
Start Price:
$35.84
ACOR Score:
+41.91
Run-up, high current, high book
Recs
elica
(< 20)
Submitted: 2/18/2010 10:58:45 AM :
Start Price:
$32.20
ACOR Score:
-42.63
great tech signs
Recs
Johnsora
(61.90)
Submitted: 1/23/2010 12:19:06 PM :
Start Price:
$23.29
ACOR Score:
-20.29
The MS drug has finally been approved. A family member who has MS brought to my attention. Their doctor told them about it and has a list of clients ready to get prescriptions once available. I was also told this is the first MS drug that works for all types of MS. Big sales are on the horizon.
Recs
GreatStocks3728
(< 20)
Submitted: 1/23/2010 9:16:54 AM :
Start Price:
$28.25
ACOR Score:
-31.86
Great earnings ahead.
Recs
preston18
(< 20)
Submitted: 10/7/2009 5:25:30 PM :
Start Price:
$23.13
ACOR Score:
-16.11
Outperform
Recs
Hogty
(41.50)
Submitted: 9/1/2009 1:12:01 PM :
Start Price:
$21.87
ACOR Score:
+18.33
Overvalued. If you want in on the future of CNS research and production invest in a broader, safer buy like STEM. They will benefit from the production and storage regardless of who comes up with the new tech. Short the fall. Not sure when or if I would buy back in.
Recs
TMFBiologyFool
(97.67)
Submitted: 7/1/2009 5:35:48 PM :
Start Price:
$24.90
ACOR Score:
-45.98
FDA approval seems likely.
Recs
mjules2b
(< 20)
Submitted: 4/30/2009 2:37:46 PM :
Start Price:
$19.68
ACOR Score:
-25.64
I remember when I first purchase this stock at $ 6 something a share and drop to $ 1. it was very downgrade, I thought I made a mistake. So a year later $ 175000 was sitting on my back pocket, that's worth the price. From $ 1 to almost $ 36 a share, that's called trading, with no experience. It's worth the try...
Recs
pick1998
(86.37)
Submitted: 2/26/2009 7:26:27 PM :
Start Price:
$23.38
ACOR Score:
-75.91
very promising MS drug Fampridine that helps MS patients walk better. NDA filed on Jan, 09, expected to be approved by end of 2009. Another good trait is that it is in form of oral pills.
Recs
jmacn22
(86.65)
Submitted: 2/5/2009 1:04:25 PM :
Start Price:
$24.46
ACOR Score:
+56.92
Underperform
Recs
Recs
ScreenerStizBear
(< 20)
Submitted: 6/26/2008 2:26:22 PM :
Start Price:
$31.31
ACOR Score:
+26.21
I simply used the screener to identify 1-star companies with the highest 52-week gain. The 1-star rating should mean they are bad companies and the 52-week gain should mean they are overpriced. We’ll see how it works!
RSS Headlines
Fool UK
- Show Me:
-
Outperform
-
Underperform
-
All
- Sort by:
-
Author
-
Recs
-
Date
-
Member Rating
-
Results 1 - 20 of 40 : 1 2 Next »